FORMULATION AND EVALUATION OF PULSATILE DRUG DELIVERY SYSTEM OF SALBUTAMOL SULFATE FOR THE CHRONOTHERAPY OF ASTHMA
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i9.20423Keywords:
Salbutamol sulfate, Nocturnal asthma, Time-controlled pulsatile tablet, Press-coated tablet, 6 h lag time, Burst releaseAbstract
Objective: The main objective of the present study was to design and evaluate a time-controlled single unit oral pulsatile drug delivery system containing salbutamol sulfate for the prevention of nocturnal asthma attacks.
Methods: Drug containing core tablets (C1-C10) with different composition of superdisintegrants such as sodium starch glycolate, croscarmellose sodium, and crospovidone were prepared by direct compression technique. The fast disintegrating core tablet formulation was selected, and press-coated tablets (P1-P11) were prepared with different compositions of hydrophobic and hydrophilic polymers: Ethylcellulose-20 (EC-20), hydroxypropyl methylcellulose K4M, and low substituted hydroxypropyl cellulose (L-HPC LH11). The coating polymers were selected and quantified based on in vitro lag time and drug release profile in simulated gastric and intestinal fluids.
Results: Formulation C10 with 7.5% crospovidone showed least disintegrating time, i.e., 0.31 min and was selected as the best immediate release core tablet. The press-coated tablet formulation P11 having 360 mg barrier layer of EC-20 and L-HPC LH11 in ratio 14:1 over the core tablet C10 showed rapid and complete drug release nearly after 6 h lag time. Accelerated stability studies of the optimized formulation P11 indicated no significant difference in release profile after a period of 6 months.
Conclusion: The in vitro dissolution study showed that lag time before drug release was highly affected by the coating level and nature of coating polymer used. Time-controlled pulsatile release tablets can be prepared using press-coating techniques.
Downloads
References
Hussain SK, Firoz S, Ramya EM, Sarada K, Ramesh B, Jagadesh K. A review of chronopharmaceutical drug delivery system. Int J Med Pharm Res 2015;3:942-7.
Kumar JP, Muzib YI, Misra G. Preparation and evaluation of pulsatile drug delivery of fluvastatin sodium. Asian J Pharm Clin Res 2016;9:348 51.
Rewar S, Bansal BK, Singh CJ, Sharma AK. Pulsatile drug delivery release technologies: An overview. Int J Res Dev Pharm Life Sci 2015;4:1386-93.
Bhuvaneswari S, Manivannan S, Akshay M, Nify F. Formulation and evaluation of gastroretentive microballoons of Acebrophylline for the treatment of bronchial asthma. Asian J Pharm Clin Res 2016;9:105-11.
Chandra JR, Arora K, Anuragi N, Kaushal R, Jain V. Pulsatile drug delivery system: A promising delivery system for controlled drug release. Eur J Pharm Med Res 2015;2:564-75.
Richard JM. Nocturnal asthma: Circardian rhythms and therapeutic interventions. Am Rev Respir Dis Suppl Airway Dis Update 1993;147:S25-8.
Global Strategy for Asthma Management and Prevention. GINA Appendix 2015 Update. Mechanisms of Asthma; 2015. p. 21.
Richard JM, Schlegel SB. Chronobiology of asthma. Am J Respir Crit Care Med 1998;158:1002-7.
Tripathi KD. Essentials of Medical Pharmacology. 6th ed. New Delhi, India: Jaypee Brothers Medical Publishers; 2010. p. 216-27.
Goldstein DA, Tan YK, Soldin SJ. Pharmacokinetics and absolute bioavailability of Salbutamol in healthy adult volunteers. Eur J Clin Pharmacol 1987;32:631-4.
Drug Bank. Available from: http://www.drugbank.ca/drugs/DB01001. [Last accessed on 2016 Jan 29].
Kumar A, Maurya R. Formulation and evaluation of press-coated pulsatile tablets of salbutamol sulphate. J Sci Innov Res 2012;1:74-87.
Patel T, Ananthapur M, Sabitha JS, Tribedi S, Mathappan R, Prasanth VV. Formulation and evaluation of erodible pulsatile drug delivery system of Salbutamol sulphate for nocturnal asthma. Int J Pharm Innov 2013;3:24-35.
Malladi M, Jukanti R. Floating pulsatile drug delivery system of famotidine: Design, statistical optimization, and in vitro evaluation. Int J Pharm Sci 2016;8:169-81.
Wadhwa R, Sharma Y, Upadhyay RP, Bala K. Pulsatile release of ketoprofen from compression coated tablets using eudragit® polymers. Int J Pharm Pharm Sci 2016;8:224-9
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.